Patents by Inventor Eleonora Trotta

Eleonora Trotta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12103958
    Abstract: The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules. The invention includes uses, and associated methods of using the LFA3 polypeptide molecules.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: October 1, 2024
    Assignees: Pfizer Inc., The Regents of the University of California
    Inventors: Natasha Kay Crellin, Lauren Kate Ely, Jason Robles Reyes, Chia Chi Ho, Jeffrey A. Bluestone, Eleonora Trotta, Qizhi Tang
  • Publication number: 20230340106
    Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.
    Type: Application
    Filed: September 16, 2022
    Publication date: October 26, 2023
    Applicants: Pfizer Inc., The Regents of the University of California, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Isaac J. Rondon, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
  • Patent number: 11459385
    Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: October 4, 2022
    Assignees: The Regents of the University of California, The Board of Trustees of the Leland Stanford Junior University, Pfizer, Inc.
    Inventors: Isaac J. Rondon, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
  • Publication number: 20210061902
    Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.
    Type: Application
    Filed: July 9, 2020
    Publication date: March 4, 2021
    Inventors: Isaac J. RONDON, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
  • Publication number: 20210032308
    Abstract: The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules. The invention includes uses, and associated methods of using the LFA3 polypeptide molecules.
    Type: Application
    Filed: September 28, 2020
    Publication date: February 4, 2021
    Inventors: Natasha Kay CRELLIN, Lauren Kate ELY, Jason Robles REYES, Chia Chi HO, Jeffrey A. BLUESTONE, Eleonora TROTTA, Qizhi TANG
  • Patent number: 10738113
    Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: August 11, 2020
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, PFIZER INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Isaac J. Rondon, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
  • Publication number: 20190106488
    Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.
    Type: Application
    Filed: September 18, 2018
    Publication date: April 11, 2019
    Inventors: Isaac J. Rondon, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
  • Patent number: 10138298
    Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: November 27, 2018
    Assignees: The Regents of the University of California, The Board of Trustees of the Leland Stanford Junior University, Pfizer Inc.
    Inventors: Isaac J. Rondon, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
  • Publication number: 20170114130
    Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.
    Type: Application
    Filed: October 21, 2016
    Publication date: April 27, 2017
    Inventors: Isaac J. Rondon, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia